Cargando…

Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study

In patients with multiple myeloma (MM), SARS-CoV-2 infection has been associated with a severe clinical course and high mortality rates due to the concomitant disease- and treatment-related immunosuppression. Specific antiviral treatment involves viral replication control with monoclonal antibodies...

Descripción completa

Detalles Bibliográficos
Autores principales: Spiliopoulou, Vassiliki, Ntanasis-Stathopoulos, Ioannis, Malandrakis, Panagiotis, Gavriatopoulou, Maria, Theodorakakou, Foteini, Fotiou, Despina, Migkou, Magdalini, Roussou, Maria, Eleutherakis-Papaiakovou, Evangelos, Kastritis, Efstathios, Dimopoulos, Meletios A., Terpos, Evangelos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054373/
https://www.ncbi.nlm.nih.gov/pubmed/36992413
http://dx.doi.org/10.3390/v15030704
_version_ 1785015654754025472
author Spiliopoulou, Vassiliki
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Gavriatopoulou, Maria
Theodorakakou, Foteini
Fotiou, Despina
Migkou, Magdalini
Roussou, Maria
Eleutherakis-Papaiakovou, Evangelos
Kastritis, Efstathios
Dimopoulos, Meletios A.
Terpos, Evangelos
author_facet Spiliopoulou, Vassiliki
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Gavriatopoulou, Maria
Theodorakakou, Foteini
Fotiou, Despina
Migkou, Magdalini
Roussou, Maria
Eleutherakis-Papaiakovou, Evangelos
Kastritis, Efstathios
Dimopoulos, Meletios A.
Terpos, Evangelos
author_sort Spiliopoulou, Vassiliki
collection PubMed
description In patients with multiple myeloma (MM), SARS-CoV-2 infection has been associated with a severe clinical course and high mortality rates due to the concomitant disease- and treatment-related immunosuppression. Specific antiviral treatment involves viral replication control with monoclonal antibodies and antivirals, including molnupiravir and the ritonavir-boosted nirmatrelvir. This prospective study investigated the effect of these two agents on SARS-CoV-2 infection severity and mortality in patients with MM. Patients received either ritonavir-nirmatrelvir or molnupiravir. Baseline demographic and clinical characteristics, as well as levels of neutralizing antibodies (NAbs), were compared. A total of 139 patients was treated with ritonavir-nirmatrelvir while the remaining 30 patients were treated with molnupiravir. In total, 149 patients (88.2%) had a mild infection, 15 (8.9%) had a moderate infection, and five (3%) had severe COVID-19. No differences in the severity of COVID-19-related outcomes were observed between the two antivirals. Patients with severe disease had lower neutralizing antibody levels before the COVID-19 infection compared to patients with mild disease (p = 0.04). Regarding treatment, it was observed that patients receiving belantamab mafodotin had a higher risk of severe COVID-19 (p < 0.001) in the univariate analysis. In conclusion, ritonavir-nirmatrelvir and molnupiravirmay prevent severe disease in MM patients with SARS-CoV-2 infection. This prospective study indicated the comparable effects of the two treatment options, providing an insight for further research in preventing severe COVID-19 in patients with hematologic malignancies.
format Online
Article
Text
id pubmed-10054373
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100543732023-03-30 Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study Spiliopoulou, Vassiliki Ntanasis-Stathopoulos, Ioannis Malandrakis, Panagiotis Gavriatopoulou, Maria Theodorakakou, Foteini Fotiou, Despina Migkou, Magdalini Roussou, Maria Eleutherakis-Papaiakovou, Evangelos Kastritis, Efstathios Dimopoulos, Meletios A. Terpos, Evangelos Viruses Communication In patients with multiple myeloma (MM), SARS-CoV-2 infection has been associated with a severe clinical course and high mortality rates due to the concomitant disease- and treatment-related immunosuppression. Specific antiviral treatment involves viral replication control with monoclonal antibodies and antivirals, including molnupiravir and the ritonavir-boosted nirmatrelvir. This prospective study investigated the effect of these two agents on SARS-CoV-2 infection severity and mortality in patients with MM. Patients received either ritonavir-nirmatrelvir or molnupiravir. Baseline demographic and clinical characteristics, as well as levels of neutralizing antibodies (NAbs), were compared. A total of 139 patients was treated with ritonavir-nirmatrelvir while the remaining 30 patients were treated with molnupiravir. In total, 149 patients (88.2%) had a mild infection, 15 (8.9%) had a moderate infection, and five (3%) had severe COVID-19. No differences in the severity of COVID-19-related outcomes were observed between the two antivirals. Patients with severe disease had lower neutralizing antibody levels before the COVID-19 infection compared to patients with mild disease (p = 0.04). Regarding treatment, it was observed that patients receiving belantamab mafodotin had a higher risk of severe COVID-19 (p < 0.001) in the univariate analysis. In conclusion, ritonavir-nirmatrelvir and molnupiravirmay prevent severe disease in MM patients with SARS-CoV-2 infection. This prospective study indicated the comparable effects of the two treatment options, providing an insight for further research in preventing severe COVID-19 in patients with hematologic malignancies. MDPI 2023-03-08 /pmc/articles/PMC10054373/ /pubmed/36992413 http://dx.doi.org/10.3390/v15030704 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Spiliopoulou, Vassiliki
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Gavriatopoulou, Maria
Theodorakakou, Foteini
Fotiou, Despina
Migkou, Magdalini
Roussou, Maria
Eleutherakis-Papaiakovou, Evangelos
Kastritis, Efstathios
Dimopoulos, Meletios A.
Terpos, Evangelos
Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
title Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
title_full Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
title_fullStr Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
title_full_unstemmed Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
title_short Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
title_sort use of oral antivirals ritonavir-nirmatrelvir and molnupiravir in patients with multiple myeloma is associated with low rates of severe covid-19: a single-center, prospective study
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054373/
https://www.ncbi.nlm.nih.gov/pubmed/36992413
http://dx.doi.org/10.3390/v15030704
work_keys_str_mv AT spiliopoulouvassiliki useoforalantiviralsritonavirnirmatrelvirandmolnupiravirinpatientswithmultiplemyelomaisassociatedwithlowratesofseverecovid19asinglecenterprospectivestudy
AT ntanasisstathopoulosioannis useoforalantiviralsritonavirnirmatrelvirandmolnupiravirinpatientswithmultiplemyelomaisassociatedwithlowratesofseverecovid19asinglecenterprospectivestudy
AT malandrakispanagiotis useoforalantiviralsritonavirnirmatrelvirandmolnupiravirinpatientswithmultiplemyelomaisassociatedwithlowratesofseverecovid19asinglecenterprospectivestudy
AT gavriatopouloumaria useoforalantiviralsritonavirnirmatrelvirandmolnupiravirinpatientswithmultiplemyelomaisassociatedwithlowratesofseverecovid19asinglecenterprospectivestudy
AT theodorakakoufoteini useoforalantiviralsritonavirnirmatrelvirandmolnupiravirinpatientswithmultiplemyelomaisassociatedwithlowratesofseverecovid19asinglecenterprospectivestudy
AT fotioudespina useoforalantiviralsritonavirnirmatrelvirandmolnupiravirinpatientswithmultiplemyelomaisassociatedwithlowratesofseverecovid19asinglecenterprospectivestudy
AT migkoumagdalini useoforalantiviralsritonavirnirmatrelvirandmolnupiravirinpatientswithmultiplemyelomaisassociatedwithlowratesofseverecovid19asinglecenterprospectivestudy
AT roussoumaria useoforalantiviralsritonavirnirmatrelvirandmolnupiravirinpatientswithmultiplemyelomaisassociatedwithlowratesofseverecovid19asinglecenterprospectivestudy
AT eleutherakispapaiakovouevangelos useoforalantiviralsritonavirnirmatrelvirandmolnupiravirinpatientswithmultiplemyelomaisassociatedwithlowratesofseverecovid19asinglecenterprospectivestudy
AT kastritisefstathios useoforalantiviralsritonavirnirmatrelvirandmolnupiravirinpatientswithmultiplemyelomaisassociatedwithlowratesofseverecovid19asinglecenterprospectivestudy
AT dimopoulosmeletiosa useoforalantiviralsritonavirnirmatrelvirandmolnupiravirinpatientswithmultiplemyelomaisassociatedwithlowratesofseverecovid19asinglecenterprospectivestudy
AT terposevangelos useoforalantiviralsritonavirnirmatrelvirandmolnupiravirinpatientswithmultiplemyelomaisassociatedwithlowratesofseverecovid19asinglecenterprospectivestudy